Darunavir, Ritonavir and Etravirine — Competitive Intelligence Brief

Darunavir, Ritonavir and Etravirine (Darunavir, Ritonavir and Etravirine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antiretroviral combination (protease inhibitor + NNRTI). Area: Infectious Disease.

marketed Antiretroviral combination (protease inhibitor + NNRTI) HIV protease, HIV reverse transcriptase Infectious Disease Small molecule

Target snapshot

Darunavir, Ritonavir and Etravirine (Darunavir, Ritonavir and Etravirine) — Imperial College London. This combination inhibits HIV protease and reverse transcriptase to block viral replication in HIV-infected patients.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Darunavir, Ritonavir and Etravirine TARGET	Darunavir, Ritonavir and Etravirine	Imperial College London	marketed	Antiretroviral combination (protease inhibitor + NNRTI)	HIV protease, HIV reverse transcriptase
Darunavir, Ritonavir and Rilpivirine	Darunavir, Ritonavir and Rilpivirine	St Stephens Aids Trust	marketed	Antiretroviral combination (protease inhibitor + NNRTI)	HIV protease, HIV reverse transcriptase
Atazanavir / Ritonavir + Tenofovir / Emtricitabine	Atazanavir / Ritonavir + Tenofovir / Emtricitabine	Juan A. Arnaiz	marketed	Antiretroviral combination (protease inhibitor + nucleoside/nucleotide reverse transcriptase inhibitors)	HIV protease, HIV reverse transcriptase
Ritonavir boosted Atazanavir + 2 NRTIs	Ritonavir boosted Atazanavir + 2 NRTIs	Fundacion SEIMC-GESIDA	marketed	Protease inhibitor combination antiretroviral therapy	HIV protease, HIV reverse transcriptase
Atazanavir, ritonavir, lamivudine	Atazanavir, ritonavir, lamivudine	Catholic University of the Sacred Heart	marketed	Antiretroviral combination (protease inhibitor + NRTI)	HIV protease, HIV reverse transcriptase
Atazanavir-Ritonavir/ Stavidine / Lamivudine	Atazanavir-Ritonavir/ Stavidine / Lamivudine	Bristol-Myers Squibb	marketed	Antiretroviral combination therapy (protease inhibitor + nucleoside reverse transcriptase inhibitors)	HIV protease, HIV reverse transcriptase
lopinavir/ritonavir; nevirapine; Zidovudine; Lamivudine	lopinavir/ritonavir; nevirapine; Zidovudine; Lamivudine	University of British Columbia	marketed	Antiretroviral combination therapy (protease inhibitor + non-nucleoside reverse transcriptase inhibitor + nucleoside reverse transcriptase inhibitors)	HIV protease, HIV reverse transcriptase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antiretroviral combination (protease inhibitor + NNRTI) class)

1. Bristol-Myers Squibb · 1 drug in this class
2. Imperial College London · 1 drug in this class
3. St Stephens Aids Trust · 1 drug in this class